Causes of Mortality by Autopsy Findings of Combat Casualties and Civilian Patients Admitted to a Burn Unit

2010 ◽  
Vol 2010 ◽  
pp. 91
Author(s):  
R.E. Salisbury
2009 ◽  
Vol 208 (3) ◽  
pp. 348-354 ◽  
Author(s):  
Ruben Gomez ◽  
Clinton K. Murray ◽  
Duane R. Hospenthal ◽  
Leopoldo C. Cancio ◽  
Evan M. Renz ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e73243 ◽  
Author(s):  
Masdalina Pane ◽  
Sholah Imari ◽  
Qomariah Alwi ◽  
I Nyoman Kandun ◽  
Alex R. Cook ◽  
...  

1963 ◽  
Vol 03 (01) ◽  
pp. 25-38
Author(s):  
Manuel Tubis ◽  
William Blahd ◽  
John Endow

SummaryA study of the removal of I131-labeled Congo red from the blood of amyloid, non-amyloid, multiple myeloma, rheumatoid arthritis and other patients is presented. The percentage removal of the labeled dye shows the same variation reported by many other workers using Bennhold’s test and its modifications.However, there seems to be a positive correlation between the percentage removal of the labeled dye and the presence of amyloid as revealed by biopsy and autopsy. The half-time of disappearance is also correlated with the amyloidosis.The availability of the I131-labeled dye permits the use of very small weights of the dye thereby drastically reducing the possibility of toxic and sometimes fatal reactions encountered with the unlabeled dye. The I131 present permits easy quantitation of the dye in the blood without separation of plasma and obviates the need of fasting. It also permits external counting and scanning of deposits in the organs containing the dye.The availability and use of the labeled dye may stimulate more comparative studies of the removal of the dye from the blood correlated with biopsy and autopsy findings.


1965 ◽  
Vol 05 (01) ◽  
pp. 1-11
Author(s):  
G. Fava ◽  
L. Roncoroni

SummaryAn account is given of the principles of lymph node dosimetry in radioisotope therapy with Lipiodol 131J. After a general introduction, exact data on the concentrations reached by the radionuclide in the lymph nodes, liver, spleen, thyroid and blood of patients subjected to this treatment are reported. Finally mention is made of a number of particularly interesting autopsy findings.


2015 ◽  
Vol 156 (15) ◽  
pp. 592-597
Author(s):  
László Szerafin ◽  
János Jakó ◽  
Ferenc Riskó

Introduction: The low peripheral absolute lymphocyte and high monocyte count have been reported to correlate with poor clinical outcome in various lymphomas and other cancers. However, a few data known about the prognostic value of absolute monocyte count in chronic lymphocytic leukaemia. Aim: The aim of the authors was to investigate the impact of absolute monocyte count measured at the time of diagnosis in patients with chronic lymphocytic leukaemia on the time to treatment and overal survival. Method: Between January 1, 2005 and December 31, 2012, 223 patients with newly-diagnosed chronic lymphocytic leukaemia were included. The rate of patients needing treatment, time to treatment, overal survival and causes of mortality based on Rai stages, CD38, ZAP-70 positivity and absolute monocyte count were analyzed. Results: Therapy was necessary in 21.1%, 57.4%, 88.9%, 88.9% and 100% of patients in Rai stage 0, I, II, III an IV, respectively; in 61.9% and 60.8% of patients exhibiting CD38 and ZAP-70 positivity, respectively; and in 76.9%, 21.2% and 66.2% of patients if the absolute monocyte count was <0.25 G/l, between 0.25–0.75 G/l and >0.75 G/l, respectively. The median time to treatment and the median overal survival were 19.5, 65, and 35.5 months; and 41.5, 65, and 49.5 months according to the three groups of monocyte counts. The relative risk of beginning the therapy was 1.62 (p<0.01) in patients with absolute monocyte count <0.25 G/l or >0.75 G/l, as compared to those with 0.25–0.75 G/l, and the risk of overal survival was 2.41 (p<0.01) in patients with absolute monocyte count lower than 0.25 G/l as compared to those with higher than 0.25 G/l. The relative risks remained significant in Rai 0 patients, too. The leading causes of mortality were infections (41.7%) and the chronic lymphocytic leukaemia (58.3%) in patients with low monocyte count, while tumours (25.9–35.3%) and other events (48.1 and11.8%) occurred in patients with medium or high monocyte counts. Conclusions: Patients with low and high monocyte counts had a shorter time to treatment compared to patients who belonged to the intermediate monocyte count group. The low absolute monocyte count was associated with increased mortality caused by infectious complications and chronic lymphocytic leukaemia. The absolute monocyte count may give additional prognostic information in Rai stage 0, too. Orv. Hetil., 2015, 156(15), 592–597.


Author(s):  
Azadi A. ◽  
Khazaei M. ◽  
Ashrafi H.

Cancer, an uncontrollable growth of cells, is among the leading causes of mortality and morbidity throughout the world. Malignant neoplasms are difficult to treat diseases because of their single in kind characteristics such as tissue invasion, metastasis, evading reticuloendothelial system (RES) and so forth. In recent decade polymeric nanoparticulate systems has gained special attention in drug delivery and targeting among all biocompatible nanoforms. Among these systems, chitosan-based hydrogel nanoparticles have been wildly utilized for drug delivery purposes. The usage of chitosan nanogels in cancer therapy significantly improved in recent years. The various cancers were the target of chitosan nanogels. Also, modification of other delivery systems with chitosan were much reported. The aim of this study is the review and update of the recent studies on chitosan nanogels applications in cancer therapy by focus on cancer based classification.


Sign in / Sign up

Export Citation Format

Share Document